Valneva will conduct investor meetings during the J.P. Morgan Healthcare Conference & Oddo BHF Forum

Read Time:2 Minute, 38 Second

VALNEVA

Saint-Herblain (France), December 21, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that members of its management team including Thomas Lingelbach, CEO and Peter Bühler, CFO will hold investor meetings during the 41st Annual J.P. Morgan Healthcare Conference, January 9 – 12, 2023 in San Francisco and the Oddo BHF Forum, January 5 – 6, 2023 in Lyon France.

Valneva’s CEO and CFO will notably discuss the Company’s current vaccine pipeline and commercial products as well as highlight Valneva’s core near- and mid-term value drivers, including its Lyme disease vaccine candidate VLA15 (Phase 3, partnered with Pfizer) and its single shot chikungunya virus vaccine candidate VLA1553 (rolling submission of biologics license application underway).

To schedule a 1on1 investor meeting with Valneva, institutional investors and analysts can contact Valneva’s investor relations department at [email protected].

About Valneva SE
Valneva, a specialty vaccine company, focuses on the production and commercialization prophylactic vaccines against infectious diseases that have a significant unmet medical demand. The Company employs a highly targeted and specialized approach to vaccine design and then uses its deep understanding of vaccine science and to develop prophylactic vaccinations that address these diseases. Valneva leveraged its knowledge and capabilities to both commercialize three vaccines as well as to quickly advance a wide range of vaccine candidates into clinics, including candidates for Lyme disease (and the chikungunya) virus.

Media & Investor Contacts
Laëtitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33(0)6 4516 7099
[email protected]

Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
[email protected]

Forward-Looking Statements
This press release contains forward-looking statements regarding the business of Valneva. These include those concerning regulatory approval of VLA1553, plans and timing for clinical programs, product candidates, and revenue forecasts. Even if Valneva’s actual results and development are in line with these forward-looking statements, they may not necessarily be indicative of future results. Forward-looking statements can be identified by words like “could”, “should”, “may,” and “may,” as well as words such “believes,” anticipates,” believes,” anticipates,” believes,” estimates,” targets, or similar words. These forward-looking statements reflect the current expectations of Valneva at the time of this press release. They are subject to unknown risks and uncertainties as well as other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied in these forward-looking statement. Uncertainties involved in vaccine development and manufacturing, unexpected clinical trial results and delays, competition in general, currency fluctuations and the impact on the global and European credit crises, as well as the ability to obtain and maintain patent or any other proprietary intellectual property protection, could affect Valneva’s expectations. There are many uncertainties and risks involved in the development and manufacture of vaccines. It is impossible to guarantee that forward-looking statements contained in this press conference will come true. Valneva has provided the information in the press release as at the date hereof. However, Valneva disclaims any obligation to update or revise any forward looking statements whether they are a result from new information or future events.

Attachment

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post F1 Bans Drivers From Making Personal, Political, and Religious Statements at Race Events
Next post Plaque revealed at Lisa Collins Classic